Cancer researchers have demonstrated a method to reprogram tumour cells into benign cells in what could be a dramatic breakthrough in the fight against the disease.
Scientists warn the method has only been trialled ‘in vitro’, and has not been tested on live human patients. But the hope is the technique may lead to a treatment for different cancers far less destructive than chemotherapy.
Cancer cells are essentially the same as normal cells, but instead of stopping the process of division during replication, they continue to divide. The result is a tumour. The instruction to stop dividing is usually controlled by microRNAs, small but critical biological markers within the cells, but something happens inside cancerous cells which stops that process.
The team at the Mayo Clinic in Florida found that by injecting human breast and bladder cancer cells with PLEKHA7 — the protein thought to stop cells dividing when added in the right quantities — they could transform cancer cells into benign cells. The insight into the role of PLEKHA7 helped the team understand how the behaviour of proteins E-cadherin and p120 catenin, which are critical for holding normal tissue together while also powering cancer division, could be regulated.
“We should be able to re-establish the brakes and restore normal cell function,” professor Panos Anastasiadis, of the Department for Cancer Biology at Mayo told The Telegraph. “Initial experiments in some aggressive types of cancer are indeed very promising.”
The study, published in Nature Cell Biology, is in theory a dramatic discovery, and if applicable in human trials would give doctors the ability to tell tumours to stop growing entirely.
“The study brings together two so-far unrelated research fields — cell-to-cell adhesion and miRNA biology — to resolve a long-standing problem about the role of adhesion proteins in cell behavior that was baffling scientists,” lead author Antonis Kourtidis said in a press statement “Most significantly, it uncovers a new strategy for cancer therapy.”
Read more: Cancer tumours ‘reprogrammed’ back into healthy tissue
The Latest on: Reprogram tumour cells
[google_news title=”” keyword=”reprogram tumour cells” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Reprogram tumour cells
- Researchers discover new pathway to cancer cell suicideon May 18, 2024 at 5:25 pm
Chemotherapy kills cancer cells. But the way these cells die appears to be different than previously understood. Researchers have now uncovered a completely new way in which cancer cells die: due to ...
- Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Teamon May 17, 2024 at 1:10 am
REDWOOD CITY, CA, USA I May 14, 2024 I Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for ...
- AbCellera: If You Build It, Will They Come? Fresh Impetus Requiredon May 16, 2024 at 5:39 am
AbCellera's valuation has shrunk by 80% since its IPO due to the withdrawal of its COVID antiviral, bamlanivimab. Read my earnings analysis of ABCL stock here.
- The CAR-T cell revolution: Reprogramming T lymphocytes against canceron May 15, 2024 at 6:33 am
A revolution in cancer treatment is here. In today’s edition, we take a look at CAR-T cell therapy or how to reprogram T lymphocytes to battle cancer. Monoclonal antibodies and CAR T cells are two ...
- How to kill the ‘zombie’ cells that make you ageon May 14, 2024 at 5:00 pm
Researchers are using new molecules, engineered immune cells and gene therapy to kill senescent cells and treat age-related diseases.
- Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Resultson May 14, 2024 at 5:08 am
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with ...
- ‘Onion structure’ vaccine triggers immune system against glioblastomaon May 13, 2024 at 8:57 am
Researchers from the University of Florida have developed a novel mRNA cancer vaccine that aims to reprogram the immune system to target and attack cancer cells effectively. The study led by Elias ...
- Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcripton May 13, 2024 at 7:48 am
Q1 2024 Earnings Call Transcript May 11, 2024 Fate Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: ...
- Scientifically Speaking | New mRNA vaccines show promise in fighting canceron May 7, 2024 at 8:30 pm
Researchers are exploring the potential of mRNA vaccines in cancer treatment, leveraging the technology's success in Covid-19 vaccines.
- Precision medicine tool predicts breast cancer immunotherapy responseon May 6, 2024 at 10:30 am
New InteractPrint tool analyzes how breast cancer epithelial cells impact cancer-immune interactions, enabling prediction of immune checkpoint inhibition response.
via Bing News